Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genfit SA (GNFT)
NASDAQ:GNFT
GNFT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.35 - $6.42
Previous CloseN/A
Volume1.39K
Average Volume (3M)9.55K
Market Cap
$190.56M
Enterprise Value$224.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)7.9
Beta0.60
Next Earnings
Apr 10, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,996,185
10 Day Avg. Volume7,715
30 Day Avg. Volume9,554
Standard Deviation0.20
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.00Price Target Upside239.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Genfit SA News
PremiumCompany Announcements
GENFIT Advances 2025 OCEANEs Repurchase with Key Agreements
PremiumCompany Announcements
GENFIT Amends Terms of 2025 OCEANEs Proposal Amid Royalty FinancingPremiumCompany Announcements
GENFIT Finalizes 2025 Bond Repurchase Terms Amidst Royalty Financing Deal
PremiumCompany Announcements
GENFIT Announces New Trials and Key Milestones in 2025
PremiumCompany Announcements
GENFIT Unveils 2025 Financial Calendar, Emphasizing Transparency---
Bulls Say, Bears Say
Bulls Say
Financial StabilityGENFIT entered into a royalty financing agreement with HealthCare Royalty for up to €185M in total funding, providing financial stability and resources for future projects.
Market OpportunityRecent U.S. approval of Iqirvo in 2L PBC, coupled with negative regulatory developments for competing agent Ocaliva, set the table for a strong launch and favorable near-term economics to GNFT in the form of milestone payments and royalties.
Regulatory ApprovalIqirvo received FDA approval for the treatment of 2L primary biliary cholangitis, along with a positive opinion from the Committee for Medicinal Products for Human Use, enhancing GENFIT's market potential.
Bears Say
Clinical And Regulatory ChallengesPotential delays in clinical and regulatory timelines pose a risk to the stock's valuation and investor confidence.
Debt ManagementPlans to eliminate outstanding convertible debt are crucial, as failure to do so may impact GENFIT's capital flexibility moving forward.
Regulatory RisksKey risks to the rating and price target include potential delays in clinical and regulatory timelines and failure to obtain regulatory approvals in additional markets.
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.93% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GNFT FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest stock price was $3.35 and its highest was $6.42 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is $190.56M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 10, 2025 which is in 47 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 19, 2024. The company reported $0.591 earnings per share for the quarter, beating the consensus estimate of $0.337 by $0.254.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.44.
How many shares outstanding does Genfit SA have?
Genfit SA has 49,996,185 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of $0.591 in its last earnings report, beating expectations of $0.337. Following the earnings report the stock price went up 15.513%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GNFT
---
Genfit SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (239.43% Upside)
$13.00 (239.43% Upside)
Blogger Sentiment
Bullish
GNFT Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 14.5%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.68%
12-Months-Change
Fundamentals
Return on Equity
26.13%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Genfit SA
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
---
GNFT Stock 12 Month Forecast
Average Price Target
$13.00
▲(239.43% Upside)
Technical Analysis
Best Analysts Covering GNFT
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
-4.07%
reiterated a buy rating 16 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -4.07% per trade.
---